Myths and Mysteries Surrounding Adjuvant Therapy for NMIBC - Ashish Kamat
September 19, 2017
Ashish Kamat, MD presents on the myths and mysteries surrounding adjuvant therapy for non-muscle invasive bladder cancer (NMIBC). Dr. Kamat explains the non-homogenous characteristics and lack of uniformity in risk factors of NMIBC. He discusses study results of BCG contribution to reduction in progression of NMIBC when maintenance is used.
For reference, PDF of slides
Additional content on NMIBC:
Emerging Therapies for BCG-Unresponsive Non-muscle Invasive Bladder Cancer- EVERYDAY UROLOGY: Full Text article
Defining and treating the spectrum of intermediate-risk NMIBC
What To Do With BCG Refractory NMIBC When Cystectomy is Not an Option?
TURBT More Important Than Ever
AUA Guidelines: Non-Muscle Invasive Bladder Cancer
Ashish Kamat, MD, MBBS, FACS, Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX; Fellowship Program Director, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX; Associate Director, Cancer Center, Reliance Foundation HN Hospital, Mumbai, India; Wayne B. Duddlesten Professorship in Cancer Research In Honor of Dr. Ashish Kamat, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston.